Stryker’s Endoscopy division acquired Ivy sports-medicine, LLC, whose portfolio is comprised of a comprehensive minimally invasive meniscal repair platform. This transaction enables Stryker to offer a complete meniscal platform. Ivy sports-medicine’s platform includes the only FDA-approved collagen meniscus implant (CMI®) on the market, as stated by the company. CMI is a biocompatible, highly purified collagen scaffold for repair and reinforcement of meniscus defects following partial meniscectomy or for the treatment of irreparable meniscus tears.The 1st implantation and U.S. launch of CMI was announced in 4Q15.
Stryker's Endoscopy division acquired Ivy sports-medicine, LLC, whose portfolio is comprised of a comprehensive minimally invasive meniscal repair platform. This transaction enables Stryker to offer a complete meniscal platform. Ivy sports-medicine's platform includes the only FDA-approved collagen meniscus implant (CMI®) on the market, as stated...
Stryker’s Endoscopy division acquired Ivy sports-medicine, LLC, whose portfolio is comprised of a comprehensive minimally invasive meniscal repair platform. This transaction enables Stryker to offer a complete meniscal platform. Ivy sports-medicine’s platform includes the only FDA-approved collagen meniscus implant (CMI®) on the market, as stated by the company. CMI is a biocompatible, highly purified collagen scaffold for repair and reinforcement of meniscus defects following partial meniscectomy or for the treatment of irreparable meniscus tears.The 1st implantation and U.S. launch of CMI was announced in 4Q15.
Copy to clipboard 
